Contents

Introduction

General Information

Tutorial
* Announcement
* Program
* Grant Application
* Challenges

Main Meeting
* Announcement
* Program

Accreditation

Committees & Faculty

Registration

Abstracts

Exhibition - Sponsorship

Hotels

© www.atomium.be - SABAM 2011 - Amanito

Main Meeting Program

From Thursday 27 to Saturday 29 October 2011

Thursday 27 October 2011 (afternoon)

SESSION 1 - Tumor Characterization: Discovery Leading to Diagnostic Development

Chairs: Maria Grazia Daidone (EU) & Tracy Lively (US)

TOPIC 1 - What Can We Learn from Large-Scale Genomic Data?

13:30 - 13:55	TCGA-Success Story in Ovarian Cancer	P. Spellman (US)
13:55 - 14:20	International Cancer Genome Consortium: a promising story in pancreatic cancer	A. Scarpa (IT)
14:20 - 15:05	Debate on Strategies for Data Release: Rapid Public Release vs. Controlled Access: - Access to Clinical Trials Data - the NSABP Experience - The METABRIC (Molecular Taxonomy of Breast Cancer Consortium) project - Generating a large genomics dataset	L. Wickerham (US) & C. Caldas (UK)
15:05 - 15:30	miRNA and Lung Cancer: Early Detection in High-Risk Subjects	G. Sozzi (IT)

 

TOPIC 2 - How Do We Handle Large-Scale Genomic Data?

16:00 - 16:25	Driving Discovery Through Data Integration and Analysis	J. Quackenbush (US)
16:25 - 16:50	Meta-Analysis of Genomic Datasets for Robust Signature Discovery and Disease Characterization	L. Wessels (NL)
16:50 - 17:30	Debate on Access to Tissue Specimens from Clinical Trials: When is the Preliminary Data Strong Enough to Invest Highly Annotated Samples?	I. Lubensky (US) & J. Hall (BE)
17:30 - 17:45	Selected abstract for oral presentation (Abs. #24): Somatic allelic selection in the tumor as an indicator of cancer relevance: insights from statistical mining of the Cancer Genome Atlas data	T. LaFramboise (US)
17:45 - 18:00	Selected abstract for oral presentation (Abs. #29): Development of a genomic-clinical classifier model for predicting clinical recurrence in patients with localized prostate cancer	E. Davicioni (CA)

 

18:00 - 20:30 POSTERS VIEWING SESSION with Walking Dinner (Grand Hall 1, Level-2)

Friday 28 October 2011 (morning)

SESSION 2 - Novel Strategies for Biomarker Design and Development

Chairs: Nadia Harbeck (EU) & Barbara Conley (US)

TOPIC 3 - Development of Omics Based Assays for Clinical Use

08:00 - 08:25	microRNAs as Prognostic and Predictive Markers in Breast Cancer	J. Martens (NL)
08:25 - 08:50	Potential Clinical Applications of Whole Genome Profiling	A. Prat (ES)
08:50 - 09:15	Omics-based tests: What is the Evidence and How to present it	J. Bogaerts (BE)
09:15 - 09:40	Requirements for Prospective Use of Omics-based tests in NCI-Sponsored Trials	L. McShane (US)
09:45 - 10:00	Selected abstract for oral presentation (Abs. #54): A genomic-based signature of response to chemotherapy in ovarian cancer fails to predict clinical outcome in two independent cohorts.	W. Barry (US)

 

TOPIC 4 - Molecular Imaging Biomarkers

10:30 - 10:55	Functional Activity Versus Clinical Predictivity	L. Shankar (US)
10:55 - 11:20	Promising Imaging Techniques for Prognosis and Prediction in Cancer	S. Stroobants (BE)
11:20 - 11:45	Integration of Metabolic Imaging (PET CT) into Clinical Trials	W. Weber (DE)
11:45 - 12:10	Translating Molecular Imaging Agents into Phase 3 Trials	P. Jacobs (US)
12:15 - 12:30	Selected abstract for oral presentation (Abs. #93): The co-development of a folate receptor molecular diagnostic imaging agent (99mTc-EC20 ) and folate receptor targeted drug conjugate (EC145) in the treatment of ovarian cancer patients.	S. Ghamande (US)

 

Friday 28 October 2011 (afternoon)

SESSION 3 - Relevant Molecular Pathways in Cancer Cells

Chairs: Jean-Yves Blay (EU) & Magdalena Thurin (US)

TOPIC 5 - Biomarker for Oncogenic Pathways: Agents in Early Development

13:30 - 13:55	Adapting Treatment in Metastatic and Adjuvant Phases to the Nature of Mutation: The Example of GIST	M. Debiec-Rychter (BE)
13:55 - 14:20	IDH1/IDH2 Mutations Predict Survival in Glioma and AML	M. Hegi (CH)
14:20 - 14:45	MDM2 inhibitors to reactivate p53 in Human Cancer	L. Vassilev (US)
14:45 - 15:10	Cancer Stem Cells	W. Matsui (US)
15:15 - 15:30	Selected abstract for oral presentation (Abs. #16): Identification of JAK2/STAT3 as a novel therapeutic target in Kras mutant colorectal cancer models	M. Kalimutho (UK)

 

TOPIC 6 - Biomarker for Oncogenic Pathways: Agents in Late Development

16:00 - 16:25	FLT3 is a Stratification Factor for Targeted Therapy Treatments in Adult and Pediatric AML-Phase III Trials	S. Meshinchi (US)
16:25 - 16:50	Predictive and Pharmacodynamic Markers of Susceptibility for Targeting IGF1R Receptor	F. Hirsch (US)
16:50 - 17:15	Various Molecular Forms of ALK Predict Sensitivity to Targeted Therapy in Hematological and Solid Tumors	M. Wasik (US)
17:15 - 17:40	Predictive and Pharmacodynamic Markers of PI3K pathway Inhibitors: focus on PI3K, Akt and mTOR inhibitors	J. Tabernero (ES)
17:45 - 18:00	Selected abstract for oral presentation (Abs. #75.): An unbiased shRNA based lentiviral screen identifies tyrosine kinases that are important for survival and radioresistance in Head and Neck Squamous Cell Carcinoma	E-J. Van Limbergen (BE)

 

Saturday 29 October 2011 (morning)

SESSION 4 - Advances in Overcoming Drug Resistance

Chairs: Dean Fennell (EU) & Francisco Esteva (US)

TOPIC 7 - Novel Insights into Molecular Mechanisms of Resistance

08:00 - 08:25	Using Genomic Landscapes to Map Biomarkers of Drug Sensitivity	U. McDermott (UK)
08:25 - 08:50	Cancer Genomics-based Mouse Models to Identify Novel Mechanisms of Drug Resistance	R. DePinho (US)
08:50 - 09:15	Epigenetics and Drug Resistance	S. Sharma (US)
09:15 - 09:40	Synthetic Lethal Approaches and Biomarker Discovery Related to Radiation Sensitization in Prostate Cancer Redundant Survival Pathways and HER2 Therapy Resistance	R. Bristow (US) F. Esteva (US)
09:45 - 10:00	Selected abstract for oral presentation (Abs. #85): Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab	K. Yonesaka (JP)

 

TOPIC 8 - Clinical Implications of Drug Resistance Biomarkers

10:30 - 10:55	Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML)	T. Lion (AT)
10:55 - 11:20	Overcoming Drug Resistance in Melanoma	J. Sosman (US)
11:20 - 11:45	Biomarkers for Targeted Therapy Selection in Non-Small Cell Lung Cancer (NSCLC)	L. Paz-Ares (ES)
11:45 - 12:10	KRAS Mutations in Colorectal Cancer (CRC): Lessons Learned and Future Progress	G. Eckhardt (US)
12:15 - 12:30	Selected abstract for oral presentation (Abs. #50): Initial experience with the EANM accreditation procedure of FDG PET/CT devices	R. Boellaard (NL)

 

[ ADJOURN ]